MBRX News and Press, Moleculin Biotech Inc. From 07/13/21

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia - Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects - Demonstr...

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases - Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases - I...

Moleculin Biotech (MBRX) to be a part of the Russell 2000 Index effective after the close of the U.S. equity markets on June 25, 2021.The Russell 2000 Index measures the performance of the small-cap segment of the US equity market.Press Release For further details s...

Moleculin Announces Inclusion in the Russell 2000® Index PR Newswire HOUSTON , June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of dr...

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases - Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 time...

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update - Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months - - Significantly strengthened financial position extends cash runway th...

Moleculin Biotech to Present at the Q2 Virtual Investor Summit Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET PR Newswire HOUSTON , May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MB...

WPD Pharmaceuticals (WPDPF) announces that it has been conditionally awarded a grant of $6.7M from the Polish National Center for Research and Development (“NCRD”), for the development of annamycin, the company’s drug candidate used in the treatment of Acute Myeloid ...

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant o...

Shares of Moleculin Biotech Inc. (NASDAQ:MBRX) traded at a new 52-week low today of $3.12. Approximately 7.7 million shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares. Moleculin Biotech Inc. share prices have moved between a 52-week high of $9...